Our findings shed new light on the therapeutic potential of targeting the circNOX4/miR-329-5p/FAP/IL-6 axis to reprogram CAFs into a quiescent state and improve clinical outcomes in NSCLC patients. The gene discussed is FAP; the disease is non-small cell lung carcinoma.